Codexis Inc Stock Price, News & Analysis

Codexis (NASDAQ: CDXS) reported strong Q2 2025 financial results with revenue of $15.3 million, surpassing analyst estimates of $14.1 million. The company strengthened its cash position by raising $27.3 million through ATM facility and Innovatus loan to support its ECO Synthesis platform expansion.

Key financial metrics include a 72% product gross margin (up from 45% in Q2 2024), R&D expenses of $13.8 million, and a net loss of $13.3 million ($0.16 per share). The company ended Q2 with $66.3 million in cash and equivalents.

Notably, Codexis' ECO Synthesis platform was featured in six presentations at TIDES USA, including three from CDMO collaborators, demonstrating strong external validation. The company now has over 30 opportunities in various stages and expects to achieve pilot-scale production of GLP-grade siRNA material in 2025.

Codexis (NASDAQ: CDXS), a provider of enzymatic solutions for therapeutic manufacturing, has scheduled its second quarter 2025 financial results announcement for August 13, 2025, after market close.

The company will host a conference call and webcast at 4:30 PM ET to discuss results and provide business updates. Investors can access the webcast through Codexis' Investor Relations website, where it will remain available for 90 days. For the live call, participants can dial 877-705-2976 (domestic) or 201-689-8798 (international).

Codexis (NASDAQ: CDXS), a provider of enzymatic solutions for therapeutics manufacturing, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The event will take place from June 3-5, 2025 in New York.

The company's management will engage in a fireside chat on June 4, 2025, at 3:10 pm ET. Investors can access a live webcast of the presentation through Codexis's investor relations website, with a replay available for 90 days after the event.

Codexis (NASDAQ: CDXS) reported Q1 2025 financial results with total revenues of $7.5 million, down from $17.1 million in Q1 2024. The company secured its first revenue-generating contract for ECO Synthesis™ manufacturing services and maintained a strong cash position of $59.8 million. Net loss widened to $20.7 million ($0.25 per share) compared to $11.5 million ($0.16 per share) in Q1 2024. Product gross margin improved to 55% from 49% year-over-year. The company reiterated its 2025 guidance with expected total revenues of $64-68 million and anticipates reaching positive cash flow by the end of 2026. Notable achievements include successful development of first-generation ECO Synthesis enzymes and new board appointments. The company expects to achieve pilot scale production of GLP-grade siRNA material and sign a GMP scale-up partner by end of 2025.

Codexis (NASDAQ: CDXS) has announced six presentations featuring its ECO Synthesis Platform at the upcoming TIDES USA annual meeting in San Diego from May 19-22, 2025. The company will showcase data demonstrating the scalability and reproducibility of its enzymatic siRNA manufacturing processes through two oral presentations and one poster.

Key presentations will focus on: oligonucleotide CMC for sustainable siRNA manufacturing, comparative analysis of diastereomeric distribution in siRNA synthesis, and machine learning-guided ligation fragment design. Additionally, three CDMOs will present data on Codexis' double-stranded RNA ligases, including a co-presentation with Bachem.

The company will host a conference call on May 22, 2025, at 8:00 am ET to discuss the presented data. Attendees can visit Codexis at Booth #619, with advance appointments available through their website.

Codexis (NASDAQ: CDXS), a provider of enzymatic solutions for therapeutics manufacturing, has scheduled its first quarter 2025 financial results announcement for May 14, 2025, after market close.

The company will host a conference call and webcast at 4:30 pm Eastern Time to discuss financial performance and provide business updates. Investors can access the live webcast through the Codexis Investor Relations website, where it will remain available for 90 days.

For those preferring telephone access, the live call can be joined by dialing:

• Domestic: 877-705-2976
• International: 201-689-8798

A 48-hour telephone replay will be available using:

• Domestic: 877-660-6853
• International: 201-612-7415
• Access ID: 13726635

Codexis (NASDAQ: CDXS) announced that Byron Dorgan will retire from its Board of Directors at the 2025 Annual Meeting of Stockholders. Dorgan, who joined the Board in 2011 and served as Chairman from 2021 through 2024, currently chairs the Nominating and Corporate Governance Committee.

Following his departure, Dorgan will continue as a consultant to Codexis for one year. The company will reduce its Board seats from ten to nine. During his tenure, Dorgan contributed to Codexis's transformation into a leading therapeutics manufacturing company, particularly in advancing solutions like the ECO Synthesis platform.

Codexis (NASDAQ: CDXS) has appointed Cynthia Collins to its Board of Directors. Collins, currently serving as Executive Chair and interim CEO of Nutcracker Therapeutics, brings over four decades of pharmaceutical and biotech industry experience. She previously served as CEO of Editas Medicine, where she led the first clinical trial of in vivo CRISPR gene editing therapy.

Collins' extensive leadership experience includes roles as CEO of Human Longevity, various executive positions at GE Healthcare, CEO of GenVec, and president of oncology at Baxter Healthcare. She currently serves on multiple boards including Certara, MaxCyte, and DermTech. The appointment aims to support Codexis' expansion of their ECO Synthesis toolbox in the RNA therapeutics space.

Codexis (NASDAQ: CDXS) has secured its first revenue-generating contract for manufacturing siRNA material using their ECO Synthesis™ Innovation Lab. The company has successfully developed and validated the first generation of core ECO Synthesis™ enzymes, meeting pre-specified criteria for industrial-scale production.

This milestone follows their previous achievements in dsRNA ligation offerings. The company plans to demonstrate process parameters that are comparable to or potentially superior to traditional chemical methods at upcoming scientific meetings.